NextPharma Technologies Announces the Opening of a Sales Representative Office in Japan
Surrey, UK, 1st October, 2008
NextPharma the leading European provider of product development, contract manufacturing and cold chain and logistics outsourcing services to the pharmaceutical and biotech industry, is pleased to announce the opening of a Sales Representative Office in Nagoya – Japan managed by Leslie Pryce and has appointed Kai Siegmund as our Japanese speaking marketing manager in Europe.
The decision to expand services to Japan has been taken in relation to NextPharma’s growing business in Japan – the World’s second largest pharmaceutical market. Leslie Pryce head of ‘New Business Horizons consulting’ has a long standing reputation in the Asia Pacific market and has previously held a number of senior roles with GlaxoSmithKline in Korea.
Kai Siegmund’s role has been established to provide a Japanese language capability contact for NextPharma’s growing number of Japanese customers in liaison with our European and North American teams. Kai Siegmund has worked and studied in Japan and is based in Bielefeld, Germany.
Bill Wedlake, CEO, and NextPharma Technologies, commented: ‘Following on from our successful accreditation as a foreign manufacturer to Japan in 2007 we are delighted to have Leslie Pryce and Kai Siegmund on our team, both of whom have a proven track record and extensive knowledge of the Japanese market. I am convinced that both Leslie and Kai will make a significant contribution to NextPharma’s presence in Japan as we continue to expand our world class, product development, contract manufacturing and logistics services into this important market’.
NextPharma develops, manufactures, packages, and distributes a broad range of products and formulations for its customers from tablets and capsules to antibiotics, hormones and controlled release medicines. It has an established leadership position in the high technology area of injectables manufacturing (lyophilized and liquid fill), with particular expertise in product development and manufacture of oncology medicines.
Press Release PDF Download
Contact:
Franck Latrille
Chief Executive Officer
NextPharma Technologies Holding Limited
Tel.: +44 (0) 1483 479 120
Notes to Editors:
About NextPharma
NextPharma Technologies, headquartered in the UK and founded in 2000, is world class provider of product development, contract manufacturing and distribution outsourcing services to the pharmaceutical, specialty pharmaceutical, generics and biotech industry.
It offers a broad range of services from early phase product development, through clinical trials supplies to high volume commercial manufacturing. NextPharma is a world leader in lyophilization, sterile fill-finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled substances. Its sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules.
NextPharma operates globally with seven product development centres, seven manufacturing plants and six storage and distribution sites across Europe and North America employing over 1,200 people. Across these locations NextPharma has built-up a strong track record in the development and manufacture of cytotoxics, hormones, antibiotics, pellets, sterile, solid, semi-solid, liquid and dry dosage forms, supplying customers in North America, Europe and Japan.
NextPharma has a customer base, which includes many of the world's leading pharmaceutical, specialty pharma and biotech companies.